Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor

ACS Medicinal Chemistry Letters

Volumn 4, Issue 6, 2013, Pages 560-564

  Dreyfus, Nicolas ^a   Myers, Jason K ^a   Badescu, Valentina O ^a   De Frutos, Oscar ^b   De La Puente, Maria Luz ^b   Ding, Chunjin ^a   Filla, Sandra A ^a   Fynboe, Karsten ^c   Gernert, Douglas L ^a   Heinz, Beverly A ^a   Hemrick Luecke, Susan K ^a   Johnson, Kirk W ^a   Johnson, Michael P ^a   López, Pilar ^b   Love, Patrick L ^c   Martin, Laura J ^a   Masquelin, Thierry ^a   McCoy, Michael J ^a   Mendiola, Javier ^b   Morrow, Denise ^a   Muhlhauser, Mark ^a   Pascual, Gustavo ^b   Perun, Thomas J ^a   Pfeifer, Lance A ^a   Phebus, Lee A ^a   Richards, Simon J ^a   Rincón, Juan Antonio ^b   Seest, Eric P ^a   Shah, Jikesh ^a   Shaojuan, Jia ^a   Simmons, Rosa Maria A ^a   Stephenson, Gregory A ^a   Tromiczak, Eric G ^a   Thompson, Linda K ^a   Walter, Magnus W ^a   Weber, Wayne W ^a   Zarrinmayeh, Hamideh ^a   Thomas, Craig E ^a   Joshi, Elizabeth ^a   Iyengar, Smriti ^a   Johansson, Anette M ^a   more..

^a ELI LILLY AND COMPANY   (United States)

^b DCRandT   (Spain)

^c Lead Optimization Toxicology and Pharmacology   (United States)

Author keywords

MMT; Dual; NET; Pain; Reuptake inhibitor; SERT; SERT RO; SNRI

Indexed keywords

FORMALDEHYDE; NORADRENALIN TRANSPORTER; PYRROLIDINE DERIVATIVE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR;

ANIMAL CELL; ARTICLE; BEHAVIOR; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC PAIN; COMPARATIVE STUDY; CONTROLLED STUDY; DOG; DRUG CLEARANCE; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG STABILITY; HAPLORHINI; HUMAN; HUMAN CELL; NEUROTRANSMITTER UPTAKE; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; RAT;

EID: 84879090271     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400049p     Document Type: Article

References (15)

1. Stahl, S. M.; Grady, M. M.; Moret, C. M.; Briley, M. SNRIs: Their Pharmacology, Clinical Efficacy and Tolerability in Comparison with Other Classes of Antidepressants. CNS Spectrums 2005, 10 (9), 732-747.
2. Zajecka, J. M.; Albano, D. SNRIs in the Management of Acute Major Depressive Disorder. J. Clin. Psy. 2004, 65 (suppl 17), 11-18.
3. Marks, D. M.; Shah, M. J.; Patkar, A. A.; Masand, P. S.; Park, G.; Pae, C. Serotonin-Norepinephrine Reuptake Inhibitors for Pain Control: Premise and Promise. Curr. Neuropharm. 2009, 7, 331-336.
4. Smith, H. S.; Bracken, D.; Smith, J. M. Duloxetine: A Review of its Safety and Efficacy in the Management of Fibromyalgia Syndrome. J. Cent. Nerv. Syst. Dis. 2010, 2, 57-72.
5. Depoortère, R.; Meleine, M.; Bardin, L.; Aliaga, M.; Muller, E.; Ardid, D.; Newman-Tancredi, A. Milnacipran Is Active in Models of Irritable Bowel Syndrome and Abdominal Visceral Pain in Rodents. Eur. J. Pharmacol. 2011, 672, 83-87.
6. Yucel, A.; Ozyalcin, S.; Koknel Talu, G.; Kiziltan, E.; Yucel, B.; Anderson, O. K.; Arendt-Nielsen, L.; Disci, R. The Effect of Venlafaxine on Ongoing and Experimentally Induced Pain in Neuropathic Pain Patients: a Double Blind, Placebo Controlled Study. Eur. J. Pain 2005, 9, 407-416.
7. Jones, C. K.; Eastwood, B. J.; Need, A. B.; Shannon, H. E. Analgesic Effects of Serotonergic, Noradrenergic or Dual Reuptake Inhibitors in the Carrageenan Test in Rats: Evidence for Synergism between Serotonergic and Noradrenergic Reuptake. Neuropharmacology 2006, 51, 1172-1180.
8. Iyengar, S.; Webster, A. A.; Hemrick-Luecke, S. K.; Xu, J. Y.; Simmons, R. M. A. Efficacy of Duloxetine, a Potent and Balanced Serotonin-Norepinephrine Reuptake Inhibitor in Persistent Pain Models in Rats. J. Pharmacol. Exp. Ther. 2004, 311, 576-584.
9. Walter, M. W. Monoamine Reuptake Inhibitors: Highlights of Recent Research Developments. Drug Dev. Res. 2005, 65, 97-118.
10. Van Orden, L. J.; Van Dyke, P. M.; Saito, D. R.; Church, T. J.; Chang, R.; Smith, J. A. M.; Martin, W. J.; Jaw-Tsai, S.; Stangeland, E. L. Bioorg. Med. Chem. Lett. 2013, 23, 1456-1461.
11. Mendiola, J.; Garcia-Cerrada, S.; de Frutos, O.; de la Puente, M.; Gu, R. L.; Khau, V. V. Enzymatic Resolution of N-Substituted-β-prolines. Org. Process Res. Dev. 2009, 13, 292-296.
12. 11C-Labeled 2-(Phenylthio)araalkylamines. J. Med. Chem. 2000, 43, 3103-3110.
13. Cases-Thomas, M. J.; Masters, J. J.; Walter, M. W.; Campbell, G.; Haughton, L.; Gallagher, P. T.; Dobson, D. R.; Mancuso, V.; Bonnier, B.; Giard, T.; Defrance, T.; Vanmarsenille, M.; Ledgard, A.; White, C.; Ouwerkerk-Mahadevan, S.; Brunelle, F. J.; Dezutter, N. A.; Herbots, C. A.; Lienard, J. Y.; Findlay, J.; Hayhurst, L.; Boot, J.; Thompson, L. K.; Hemrick-Luecke, S. Discovery of Novel and Selective Tertiary Alcohol Containing Inhibitors of the Norepinephrine Transporter. Bioorg. Med. Chem. Lett. 2006, 16, 2022-2025.
14. Jones, C. K.; Peters, S. C.; Shannon, H. E. Efficacy of Duloxetine, a Potent and Balanced Serotonergic and Noradrenergic Reuptake Inhibitor in Inflammatory and Acute Pain Models in Rodents. J. Pharmacol. Exp. Ther. 2005, 312, 1055-63.
15. Fields, H. L.; Basbaum, A. I.; Heinricher, M. M. Central Nervous System Mechanisms of Pain Modulation. In Wall and Melzack's Textbook of Pain, 5th ed.; McMahon, S. B., Koltzenberg, M., Eds.; Elsevier, Churchill Livingstone: London, UK, 2006; pp 125-142.